Investigational Drug Details
Drug ID: | D193 |
Drug Name: | JKB-122 |
Synonyms: | -- |
Type: | Miscellany |
DrugBank ID: | -- |
DrugBank Description: | -- |
PubChem ID: | -- |
CasNo: | -- |
Repositioning for NAFLD: | No |
SMILES: | -- |
InChiKey: | -- |
Molecular Weight: | -- |
DrugBank Targets: | -- |
DrugBank MoA: | -- |
DrugBank Pharmacology: | -- |
DrugBank Indication: | -- |
Targets: | TLR4 antagonist |
Therapeutic Category: | Anti-inflammatory |
Clinical Trial Progress: | Phase 2 on-going (NCT04255069) |
Latest Progress: | Under clinical trials |

Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
---|---|---|---|---|---|---|---|
L0227 | NCT04255069 | Phase 2 | Not yet recruiting | No Results Available | June 30, 2020 | February 13, 2020 | Details |
Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
Article ID | PMID | Source | Title |
---|